文献速递间质性肺疾病呼吸危重症与机械通气

抗sFlt-1治疗在产前支气管肺发育不良模型中保护肺泡与血管生长

Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of Bronchopulmonary Dysplasia.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该研究在模拟子痫前期和绒毛膜羊膜炎的大鼠支气管肺发育不良(BPD)模型中,检验抗sFlt-1单克隆抗体对肺生长的影响。结果显示,无论产前经羊膜腔内或母体子宫动脉输注,还是产后腹腔注射,mAb治疗均改善肺结构、血管密度、右心室肥厚及肺功能,并减轻羊膜腔内毒素的不良肺效应。提示早期抗sFlt-1治疗可能成为预防BPD的新策略。

要点

  • 产前应激(子痫前期、绒毛膜羊膜炎)增加早产儿BPD风险,sFlt-1水平升高。
  • 抗sFlt-1单克隆抗体在两种大鼠BPD模型中保护肺结构和功能。
  • 产前或产后给药均有效,并预防右心室肥厚。

核心结论

  • 抗sFlt-1单克隆抗体治疗在两种产前应激大鼠BPD模型中保留肺结构和功能,并预防右心室肥厚。
  • 研究者推测早期mAb治疗可能为预防BPD提供新策略。

研究设计与样本

  • 研究为动物实验,使用两种模拟子痫前期和绒毛膜羊膜炎的产前BPD大鼠模型。
  • 子痫前期模型通过羊膜腔内注射sFlt-1诱导,绒毛膜羊膜炎模型通过羊膜腔内注射内毒素诱导。
  • mAb给药途径包括产前羊膜腔内滴注、母体子宫动脉输注或产后腹腔注射。

主要发现

  • 在子痫前期模型中,每种mAb治疗策略均改善婴儿肺结构,评估指标包括放射状肺泡计数、血管密度、右心室肥厚和肺功能。
  • 羊膜腔内内毒素的不良肺效应也可通过产前或产后mAb治疗减轻。

临床怎么用

  • 目前仅为动物模型结果,尚不能直接用于临床实践。
  • 提示未来可探索早期抗sFlt-1治疗作为预防BPD的策略。

局限性

  • 研究为大鼠模型,结果外推到人类需谨慎。
  • 原文未报告样本量、具体数值、P值等详细统计信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Pregnancies complicated by antenatal stress, including preeclampsia (PE) and chorioamnionitis (CA), increase the risk for bronchopulmonary dysplasia (BPD) in preterm infants, but biologic mechanisms linking prenatal factors with BPD are uncertain. Levels of sFlt-1 (soluble fms-like tyrosine kinase 1), an endogenous antagonist to VEGF (vascular endothelial growth factor), are increased in amniotic fluid and maternal blood in PE and associated with CA. OBJECTIVES: Because impaired VEGF signaling has been implicated in the pathogenesis of BPD, we hypothesized that fetal exposure to sFlt-1 decreases lung growth and causes abnormal lung structure and pulmonary hypertension during infancy. METHODS: To test this hypothesis, we studied the effects of anti-sFlt-1 monoclonal antibody (mAb) treatment on lung growth in two established antenatal models of BPD that mimic PE and CA induced by intraamniotic (i.a.) injections of sFlt-1 or endotoxin, respectively. In experimental PE, mAb was administered by three different approaches, including antenatal treatment by either i.a. instillation or maternal uterine artery infusion, or by postnatal intraperitoneal injections. RESULTS: With each strategy, mAb therapy improved infant lung structure as assessed by radial alveolar count, vessel density, right ventricular hypertrophy, and lung function. As found in the PE model, the adverse lung effects of i.a. endotoxin were also reduced by antenatal or postnatal mAb therapy. CONCLUSIONS: We conclude that treatment with anti-sFlt-1 mAb preserves lung structure and function and prevents right ventricular hypertrophy in two rat models of BPD of antenatal stress and speculate that early mAb therapy may provide a novel strategy for the prevention of BPD.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Wallace B, Peisl A, Seedorf G, et al. Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of Bronchopulmonary Dysplasia. Am J Respir Crit Care Med. 2018. PMID: 29268623. doi:10.1164/rccm.201707-1371OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。